Drug Profile
Research programme: Immunosynthen antibody drug conjugates - EMD Serono/Mersana Therapeutics
Latest Information Update: 26 Sep 2023
Price :
$50
*
At a glance
- Originator EMD Serono; Merck KGaA; Mersana Therapeutics
- Developer EMD Serono; Mersana Therapeutics
- Class Antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action MPYS protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer
Most Recent Events
- 26 Sep 2023 Early research development is ongoing in Cancer in USA (Parenteral) (Mersana Therapeutics pipeline, September 2023)
- 28 Apr 2023 No recent reports of development identified for research development in Cancer in USA (Parenteral)
- 28 Mar 2019 No recent reports of development identified for research development in Cancer in USA (Parenteral)